[go: up one dir, main page]

MA49700B1 - Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride - Google Patents

Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride

Info

Publication number
MA49700B1
MA49700B1 MA49700A MA49700A MA49700B1 MA 49700 B1 MA49700 B1 MA 49700B1 MA 49700 A MA49700 A MA 49700A MA 49700 A MA49700 A MA 49700A MA 49700 B1 MA49700 B1 MA 49700B1
Authority
MA
Morocco
Prior art keywords
preparation
morpholinophenyl
pyrazol
pyrimidin
acrylamide
Prior art date
Application number
MA49700A
Other languages
English (en)
Other versions
MA49700A (fr
Inventor
Hyun Ju
Sang-Ho Oh
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran Lee
Woo-Seob Shin
Dae-Gyu Park
su-min Park
Yoon-Ah Hwang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49700(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MA49700A publication Critical patent/MA49700A/fr
Publication of MA49700B1 publication Critical patent/MA49700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

La présente invention concerne un procédé amélioré pour la préparation d'un dérivé d'aminopyrimidine ou d'un sel pharmaceutiquement acceptable de celui-ci ayant une activité inhibitrice sélective vis-à-vis des protéines kinases, en particulier contre les protéines kinases pour des récepteurs du facteur de croissance épidermique mutant. La présente invention concerne également de nouveaux intermédiaires utiles pour ledit procédé et des procédés de préparation de ceux-ci.
MA49700A 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride MA49700B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (fr) 2017-07-28 2018-07-25 Procédé amélioré pour la préparation de dérivés d'aminopyrimidine

Publications (2)

Publication Number Publication Date
MA49700A MA49700A (fr) 2021-03-17
MA49700B1 true MA49700B1 (fr) 2023-09-27

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49700A MA49700B1 (fr) 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride

Country Status (31)

Country Link
US (4) US10889578B2 (fr)
EP (1) EP3658552B1 (fr)
JP (2) JP7228562B2 (fr)
KR (1) KR102688084B1 (fr)
CN (2) CN111315742B (fr)
AU (2) AU2018308038B2 (fr)
BR (1) BR112020001278A2 (fr)
CA (1) CA3070069C (fr)
CO (1) CO2020000374A2 (fr)
DK (1) DK3658552T3 (fr)
EA (1) EA202090383A1 (fr)
ES (1) ES2962961T3 (fr)
FI (1) FI3658552T3 (fr)
HR (1) HRP20231191T1 (fr)
HU (1) HUE063533T2 (fr)
IL (2) IL271973B (fr)
LT (1) LT3658552T (fr)
MA (1) MA49700B1 (fr)
MD (1) MD3658552T2 (fr)
MX (1) MX2022008743A (fr)
PH (1) PH12020500059A1 (fr)
PL (1) PL3658552T3 (fr)
PT (1) PT3658552T (fr)
RS (1) RS64654B1 (fr)
SA (2) SA522431428B1 (fr)
SG (1) SG11201913517UA (fr)
SI (1) SI3658552T1 (fr)
SM (1) SMT202300339T1 (fr)
UA (1) UA125317C2 (fr)
WO (1) WO2019022485A1 (fr)
ZA (1) ZA202001250B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49700B1 (fr) 2017-07-28 2023-09-27 Yuhan Corp Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CN116199701A (zh) * 2023-02-27 2023-06-02 安徽中医药大学 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法
WO2024241273A1 (fr) 2023-05-23 2024-11-28 Janssen Biotech, Inc. Méthodes de traitement du cancer du poumon non à petites cellules (cpnpc)
WO2025052273A1 (fr) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Méthodes pour traiter le cancer du poumon non à petites cellules

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
TW200300348A (en) 2001-11-27 2003-06-01 American Cyanamid Co 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
EP2684874B1 (fr) 2006-10-23 2017-05-17 Cephalon, Inc. Dérivés bicycliques fusionnés de 2,4-diaminopyrimidine utilisés comme inhibiteurs de alk et de c-met
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
JP2013507449A (ja) 2009-10-12 2013-03-04 ミレクシス， インコーポレイテッド ＴＢＫ１および／またはＩＫＫεの阻害剤としてのアミノ−ピリミジン化合物
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
KR101851130B1 (ko) 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
MY172110A (en) 2010-12-13 2019-11-14 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
MX2014000528A (es) 2011-07-27 2014-05-01 Astrazeneca Ab Derivados de 2- (2, 4, 5 - anilino sustituido)pirimidina como moduladores de egfr util para el tratamiento de cancer.
JP2015503505A (ja) 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
AU2012363558C1 (en) 2011-12-30 2019-08-29 Hanmi Pharm Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
EP3604294B1 (fr) * 2014-10-13 2021-05-05 Yuhan Corporation Composés et compositions de modulation des activités de kinase mutant egfr
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
MA49700B1 (fr) * 2017-07-28 2023-09-27 Yuhan Corp Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride
CN111032650A (zh) 2017-07-28 2020-04-17 株式会社柳韩洋行 可用于合成氨基嘧啶衍生物的新型中间体、其制备方法以及使用其制备氨基嘧啶衍生物的方法
US11198684B2 (en) 2017-07-28 2021-12-14 Yuhan Corporation Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
HRP20231191T1 (hr) 2024-02-02
IL271973A (en) 2020-02-27
EP3658552B1 (fr) 2023-09-13
EP3658552A1 (fr) 2020-06-03
BR112020001278A2 (pt) 2020-07-21
US20200165236A1 (en) 2020-05-28
PT3658552T (pt) 2023-11-03
EP3658552A4 (fr) 2021-06-23
NZ761156A (en) 2024-01-26
KR102688084B1 (ko) 2024-07-24
UA125317C2 (uk) 2022-02-16
IL292429B1 (en) 2023-05-01
SMT202300339T1 (it) 2023-11-13
JP7228562B2 (ja) 2023-02-24
JP7539451B2 (ja) 2024-08-23
US10889578B2 (en) 2021-01-12
CA3070069A1 (fr) 2019-01-31
AU2018308038A1 (en) 2020-01-30
SA520411112B1 (ar) 2022-02-21
EA202090383A1 (ru) 2020-06-15
WO2019022485A1 (fr) 2019-01-31
PL3658552T3 (pl) 2024-02-19
DK3658552T3 (da) 2023-11-20
IL271973B (en) 2022-08-01
LT3658552T (lt) 2023-11-27
FI3658552T3 (fi) 2023-11-16
CO2020000374A2 (es) 2020-05-05
PH12020500059A1 (en) 2020-09-28
US11286253B2 (en) 2022-03-29
US11708362B2 (en) 2023-07-25
SA522431428B1 (ar) 2024-10-21
SG11201913517UA (en) 2020-02-27
MA49700A (fr) 2021-03-17
US12187714B2 (en) 2025-01-07
CA3070069C (fr) 2024-02-20
IL292429A (en) 2022-06-01
SI3658552T1 (sl) 2023-11-30
US20220281861A1 (en) 2022-09-08
ES2962961T3 (es) 2024-03-22
JP2023027091A (ja) 2023-03-01
RS64654B1 (sr) 2023-10-31
HUE063533T2 (hu) 2024-01-28
AU2022202936A1 (en) 2022-05-26
KR20190013553A (ko) 2019-02-11
US20230312545A1 (en) 2023-10-05
MX2022008743A (es) 2023-02-02
CN116987112A (zh) 2023-11-03
AU2022202936B2 (en) 2023-04-27
IL292429B2 (en) 2023-09-01
ZA202001250B (en) 2023-04-26
CN111315742A (zh) 2020-06-19
MD3658552T2 (ro) 2024-02-29
AU2018308038B2 (en) 2022-02-03
CN111315742B (zh) 2023-09-01
US20210269427A1 (en) 2021-09-02
JP2020528440A (ja) 2020-09-24

Similar Documents

Publication Publication Date Title
MA49700B1 (fr) Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride
MA29088B1 (fr) Composes d'indazole-carboxamide.
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
SA520411120B1 (ar) مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
TW200531692A (en) Aryl aniline derivatives as β2 adrenergic receptor agonists
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
EA200801372A1 (ru) Способы получения замещенных пиримидинов
SG166828A1 (en) Aminopyrimidines useful as kinase inhibitors
ES2354824T3 (es) Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NO20070917L (no) Imidazotriaziner som protein-kinaseinhibitorer
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
ATE542814T1 (de) Pyrazinkinaseinhibitoren
DE602006019595D1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
WO2005030678A3 (fr) Agonistes ethylamino aminosubstitues du recepteur ?eta2-adrenergique
WO2006031556A3 (fr) Composes d'arylaniline a substitution amidine
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
PH12020550485A1 (en) Crystalline salts of a b-raf kinase inhibitor
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей